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Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) persist in many low- and
middle-income countries. To date, the cost-effectiveness of population-based, combined
primary and secondary prevention strategies has not been assessed. In the Pinar del Rio
province of Cuba, a comprehensive ARF/RHD control program was undertaken over
1986 – 1996. The present study analyzes the cost-effectiveness of this Cuban program.
Methods and Findings
We developed a decision tree model based on the natural history of ARF/RHD, comparing
the costs and effectiveness of the 10-year Cuban program to a “do nothing” approach. Our
population of interest was the cohort of children aged 5 – 24 years resident in Pinar del Rio
in 1986. We assessed costs and health outcomes over a lifetime horizon, and we took the
healthcare system perspective on costs but did not apply a discount rate. We used epidemi-
ologic, clinical, and direct medical cost inputs that were previously collected for publications
on the Cuban program. We estimated health gains as disability-adjusted life years (DALYs)
averted using standard approaches developed for the Global Burden of Disease studies.
Cost-effectiveness acceptability thresholds were defined by one and three times per capita
gross domestic product per DALY averted. We also conducted an uncertainty analysis
using Monte Carlo simulations and several scenario analyses exploring the impact of alter-
native assumptions about the program’s effects and costs. We found that, compared to
doing nothing, the Cuban program averted 5051 DALYs (1844 per 100,000 school-aged
children) and saved $7,848,590 (2010 USD) despite a total program cost of $202,890 over
10 years. In the scenario analyses, the program remained cost saving when a lower level of
effectiveness and a reduction in averted years of life lost were assumed. In a worst-case
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scenario including 20-fold higher costs, the program still had a 100% of being cost-effective
and an 85% chance of being cost saving.
Conclusions
A 10-year program to control ARF/RHD in Pinar del Rio, Cuba dramatically reduced morbid-
ity and premature mortality in children and young adults and was cost saving. The results of
our analysis were robust to higher program costs and more conservative assumptions
about the program’s effectiveness. It is possible that the program’s effectiveness resulted
from synergies between primary and secondary prevention strategies. The findings of this
study have implications for non-communicable disease policymaking in other resource-
limited settings.
Introduction
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) remain the most common
cardiovascular condition in children and young adults in low- and middle-income countries
[1], with high morbidity and mortality in endemic regions such as sub-Saharan Africa [2]. Dis-
parities in RHD between developing countries are due in part to gaps in the implementation of
ARF/RHD control programs [3]. Control strategies for RHD generally focus on one or more of
three approaches: 1) primary prevention, i.e., appropriately managing streptococcal pharyngi-
tis; 2) secondary prevention, i.e., finding cases of ARF/RHD and increasing rates of antibiotic
prophylaxis; or 3) medical and surgical treatment of existing cases of RHD to prevent prema-
ture death [4].
Cost-effectiveness analysis is an important tool for decision makers seeking to implement
ARF/RHD control measures, especially in settings where the disease burden is high but inter-
vention coverage and public sector budgets are low [5]. Previously published economic evalua-
tions on ARF/RHD have focused on one of two questions. First, several studies have compared
clinical algorithms for managing pharyngitis (primary prevention) in, e.g., the United States [6,
7], and South Africa [8]. Secondly, other studies have sought to assess tradeoffs between alter-
native strategies for RHD prevention [5, 9, 10]. These studies generally place primary and sec-
ondary prevention strategies at odds with each other and often find secondary prevention (in
isolation) to be more cost-effective [5, 10].
By contrast, the World Health Organization has recommended that ARF/RHD programs be
comprehensive in scope and include scale up of primary and secondary prevention, communi-
ty education, and surveillance activities [11]. Experience in the United States during the mid-
20th century [12] and more recently, in the Latin America and Caribbean region [13, 14]
suggests that dramatic reductions in the incidence of ARF—and thus the burden of RHD—are
feasible with concerted public health efforts. In particular, a 10-year program in the Pinar del
Rio province of Cuba observed large reductions in the burden of ARF and RHD and medical
expenditures on these conditions [14].
Despite these observations, the cost-effectiveness of comprehensive ARF/RHD control ef-
forts has not been determined. At present, the controversies in the literature, e.g., whether pri-
mary prevention should be emphasized over secondary prevention [2, 5] and the role of
echocardiography-based screening [10], have not considered the empirical data from countries
that have successfully eliminated ARF and RHD through comprehensive control programs.
The aforementioned experiences in the United States, Cuba, and Costa Rica suggest that a
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comprehensive program may be highly cost-effective or even cost saving, in contrast to pro-
gram focusing only on secondary prevention. Hence a formal cost-effectiveness analysis of this
type of program could have immediate applicability to policymakers in endemic regions. In the
present study, we use previously published data from the Cuban program in Pinar del Rio
province [14] to assess the cost-effectiveness of a comprehensive effort to control ARF/RHD.
Materials and Methods
Background and Setting
Pinar del Rio is a mostly urban province of 10,931 km2 in the western part of Cuba, with
721,800 population in 1996. Nordet et al. described in detail the design and implementation of
a primary healthcare-oriented program to reduce the burden of ARF/RHD in the province
[14]. The program included community and healthcare provider education and training
around treatment of sore throat and prevention of ARF and RHD (primary prevention) as well
as development of an ARF/RHD register and improvement of patient adherence to penicillin
prophylaxis (secondary prevention). Prevalence of RHD in school-aged children was measured
before and after the program, and they also recorded the incidence of new-onset and recurrent
ARF in their province. The authors reported a progressive decline in the incidence of ARF and
severity of RHD in the province over the study period, and the effects were sustained at follow-
up six years after the program was completed [14].
Modeling Approach
We conducted a cost-utility analysis using disability-adjusted life years (DALYs) as the mea-
sure of the health burden of ARF and RHD. We compared the Pinar del Rio program with a
“do nothing” approach, because at a national level, there was no change in mortality from ARF
and RHD over the same time period [15], and similar RHD control efforts had not yet been
scaled up in the rest of Cuba. Based on our clinical experience, we developed a decision tree to
represent the various disease states associated with ARF and RHD (Fig. 1). We used this deci-
sion tree to estimate—for both the intervention and “do nothing” approaches—the total num-
ber of cases of ARF and RHD in each of these states.
For our model cohort, we used the population of children and young adults aged 5–24 years
that were residing in Pinar del Rio in 1986, the program’s index year (n = 273,933). This al-
lowed us to replicate the epidemiological data and program costs reported by Nordet et al. We
chose the healthcare system (government) perspective on costs, reflecting the fact that Cuba’s
economy is centrally planned and because no household costs were available. Our analytic ho-
rizon was the lifetime of the cohort, but as the major effects of the program occurred in the
past, we chose not to discount costs and health outcomes.
Epidemiologic and Clinical Inputs
Our decision tree incorporated the changes in ARF incidence that were measured by Nordet
et al. [14] and Lopez [16] during the program. We also used age-standardized ARF and RHD
mortality rates over 1986–1996 published by the CubanMinistry of Health [15] to calculate
case-fatality rates. For the do-nothing approach, we assumed constant incidence rates of ARF
and RHD, because as mentioned previously, this was observed throughout the rest of Cuba dur-
ing the study period. The key epidemiologic parameters are listed in Table 1. We estimated the
rest of the transition probabilities in our decision tree using aggregated data on ARF and RHD
morbidity reported by Nordet et al. and Lopez. The Supporting Information describes these cal-
culations in more detail (S1 File) and provides a full list of transition probabilities (S1 Table).
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Estimation of Program Costs
The RHD control program in Pinar del Rio involved several major components: administra-
tion, education, surveillance, and external evaluation. To estimate the time cost of the program,
we used standard Cuban wage rates, converted and inflated to 2010 US dollars, for all staff and
providers involved in the program (Ministry of Health—personal communication). We also in-
cluded the cost of the technologies used in the prevalence studies and the media costs associat-
ed with the health education campaigns [16]. Finally, we calculated the cost of an external
program evaluation that was conducted by the World Health Organization. The Supporting In-
formation (S1 File, S2 Table) provides the details of the costing process.
Estimation of Direct Medical Costs
Clinical care was and is still provided free of charge to Cuban citizens, so estimates of the direct
costs of medical care are not readily available. In order to estimate the healthcare system cost of
providing medical care, we used the prices of medical services that were charged to visitors of
Cuba during the study period [16]. We defined major cost categories as those associated with
hospitalization for 1) ARF, 2) mild-moderate RHD, 3) severe RHD leading to heart failure, and
4) severe RHD requiring surgical valve replacement. We also calculated lifetime medical costs
including follow-up diagnostics, medications, and provider fees. We separately included the
cost of secondary prophylaxis at 1986 adherence levels (control scenario, 68.3%) and 1996 ad-
herence levels (intervention scenario, 96.9%). The final cost estimates are listed in Table 2; indi-
vidual components are detailed in the Supporting Information (S3 Table).
Fig 1. Decision analysis model used in the study.
doi:10.1371/journal.pone.0121363.g001
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Estimation of Disability-Adjusted Life Years
In order to account for differential health gains by age, as well as the differential improvement
in utility experienced by patients with RHD of varying severity, we calculated all health out-
comes in terms of DALYs. Age-specific years of life lost (YLL) were calculated using formulas
developed for the Global Burden of Disease (GBD) studies [17, 18]. Years lived with disability
(YLD) were calculated using GBD 2010 disability weights [19]. Consistent with prior GBD
studies, we assumed the duration of chronic RHD was five years, followed by death.[17] Fur-
ther details on the DALY calculations are described in the Supporting Information (S1 File).
Uncertainty and Scenario Analyses
Although the original studies by Nordet et al. [14] and Lopez [16] reported point estimates of
changes in disease severity and medical expenditures, we attempted to account for uncertainty
associated with the clinical and cost data we used as inputs for our model. We thus calculated
minimum and maximum values for all transition probabilities using ranges published in the lit-
erature or, more frequently, using standard error formulas for binomial variables. We varied
the direct medical costs and program costs from 50% to 200% of the baseline estimate. To
model the joint uncertainty in all of our parameters, we calculated the DALYs and costs in
1000 Monte Carlo simulations. For each simulation, we drew transition probabilities from beta
Table 1. Main epidemiologic inputs to the model.
Control Intervention Source
Incidence of ARF
1986 12.2 / 100,000 12.2 / 100,000 Nordet et al.[14]
1987 12.2 / 100,000 7.4/ 100,000 Nordet et al.[14]
1988 12.2 / 100,000 2.6 / 100,000 Nordet et al.[14]
1989 12.2 / 100,000 2.7 / 100,000 Nordet et al.[14]
1990 12.2 / 100,000 2.8 / 100,000 Nordet et al.[14]
1991 12.2 / 100,000 3.0 / 100,000 Nordet et al.[14]
1992 12.2 / 100,000 3.2 / 100,000 Nordet et al.[14]
1993 12.2 / 100,000 4.1 / 100,000 Nordet et al.[14]
1994 12.2 / 100,000 1.9 / 100,000 Nordet et al.[14]
1995 12.2 / 100,000 2.0 / 100,000 Nordet et al.[14]
ARF case-fatality rate * 0.014 0.014 MINSAP[15]
RHD case-fatality rate
With ﬁrst ARF ** episode 0.357 0.000 Lopez[16]
With recurrent ARF ** 0.444 0.000 Lopez[16]
With progression of RHD 0.385 0.000 Lopez[16]
Probability of ARF recurrence
With history of ARF 0.567 0.176 Lopez[16]
With history of RHD 0.778 0.250 Lopez[16]
Probability of requiring surgery 0.071–0.154 0.044–0.060
First presentation with RHD 0.071 0.000 Lopez[16]
Progression of RHD 0.154 0.000 Lopez[16]
Null case-fatality rates were varied in the uncertainty analysis (S1 Table).
* Estimated from published RHD mortality rates and calculated incidence rates.
** “RHD mortality” in this case reﬂects presence of severe carditis with ARF.
doi:10.1371/journal.pone.0121363.t001
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distributions parameterized by their upper and lower bounds, and we drew costs from a ran-
dom uniform distribution.
We identified three critical assumptions inherent in our model and thus tested their impact
on our estimates in four scenario analyses. First, secular trends in RHD globally between 1990
and 2010 suggest that the yearly decline in the burden of RHD was approximately 2.5% [20], so
we incorporated the same linear decline in ARF incidence in our “do nothing” approach. Sec-
ond, there were no local data to support the five year average duration of RHD used in the
GBD studies to calculate YLL [17], so we increased the duration to 20 years to understand the
impact this would have on total YLL averted. Third because wages in Cuba during the study pe-
riod were quite low (owing to the country’s unique economy) and the true economic cost of
the program in a similar developing country setting in the present day might actually be much
higher, we increased the program costs 20-fold. Fourth, we created a “worst case” scenario that
simultaneously incorporated all three prior scenario analyses. Similar to the base case, we per-
formed 1000 simulations to quantify uncertainty associated with each scenario analysis.
Other Methods
As mentioned above, in the base case we used an exchange rate of 1 Cuban Pesos to 1 US dollar,
which was the formal government exchange rate during the 1980s. We inflated all costs to 2010
US dollars using consumer price index information from the World Bank [21]. Because the
cost analysis was conducted on a program in the past, we did not discount the cost estimates or
DALYs. Based onWHO-CHOICE criteria, we considered the program very cost effective if the
cost per DALY averted was less than the gross domestic product (GDP) per capita and cost
Table 2. Costs associated with ARF and RHD in Pinar del Rio, Cuba.
Direct medical costs




Lifetime cost of secondary prevention *
ARF alone $3205 – $6222
ARF with RHD $7262 – $11,161
Total lifetime costs *
ARF $15,515 – $18,699
Mild-moderate RHD $21,359 – $25,259
Severe RHD $40,714 – $49,298
Surgery for RHD $56,285 – $62,532
Program costs (over a 10-year period)
Administrative costs $43,372
Educational costs—health workers $151,206
Educational costs—community $1360
Survey cost—before intervention $1796
Survey cost—after intervention $4021
External evaluation costs $1134
Total program costs $202,890
All costs in 2010 US dollars. See main text for costing methods and sources.
* Value within range depends on age at initial diagnosis.
doi:10.1371/journal.pone.0121363.t002
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effective if the cost per DALY averted was between one and three times the GDP per capita
[22]. We also followed the WHO “best buy” framework and used a threshold cost of less than
US$ 100 per DALY averted to represent a “cheap” intervention in the local context [23]. We
used World Bank estimates of gross domestic product and Cuba’s 2010 population size to ar-
rive at the following cost-effectiveness thresholds: less than US$ 5702 per DALY averted was
“very cost effective,” and between US$ 5702 and US$ 17,106 per DALY averted was “cost-
effective” [24]. Costs were estimated in Microsoft Excel 2011, and the decision tree as well as
the uncertainty and scenario analyses were developed and run in R [25]. Code for the R simula-
tions is available from the authors upon request.
Ethical considerations
Because this analysis used only publicly available or previously published data, it was deemed
“not human subjects research” according to the criteria of the University of Washington’s insti-
tutional review board. All authors had full access to the study data, reviewed the manuscript,
and provided consent for publication. The authors declare no competing interests.
Results
Base case
In a cohort of 273,933 at-risk Cuban children, implementation of the ARF/RHD program
averted 231 cases of ARF, 117 cases of RHD, and US$ 7,848,590 in total direct medical costs,
the latter of which vastly outweighed the program investments of US$ 202,890. These health
gains translated into 5051 DALYs averted, and because the program was cost saving, it domi-
nated the do-nothing approach in all 1000 Monte Carlo simulations (Table 3).
Scenario analyses
We found that modeling the global trend as the counterfactual (do-nothing) trend and increas-
ing the average duration of RHD did not substantially alter the results. When the program
costs were increased 20-fold and when the worst case scenario was modeled, the program was
not cost saving in all simulations, yet it remained “very cost effective” compared with the











Base case -$1728 100% 100% 100% 100%
(-$3154;-$942)
Lower program effectiveness -$1615 100% 100% 100% 100%
(-$3214;-$877)
Longer duration of RHD
(fewer YLLs)
-$2305 100% 100% 100% 100%
(-$4520;-$1205)
Ten-fold higher program cost -$732 94.2% 96.2% 100% 100%
(-$1875; $192)
Worst case (all the above
changes)
-$722 84.9% 88.2% 100% 100%
(-$2305; $725)
Acceptability thresholds: “best buy” is < $100/DALY; “very cost-effective” is < $5702/DALY; “cost-effective” is < $17,106/DALY. All costs in 2010 US
dollars. See main text for details of each scenario. ICER = incremental cost-effectiveness ratio.
doi:10.1371/journal.pone.0121363.t003
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do-nothing approach in all simulations. Table 3 and Fig. 2 present these results as a range of
cost-effectiveness ratios (ICERs) to aid in the interpretation of scenarios where the program
was not cost saving.
In terms of acceptability thresholds, we used the average health outcomes and savings in di-
rect medical costs to calculate the acceptable program cost under the base and worst case sce-
narios. In the base case, any program costing less than US$ 8.6 million over 10 years would be
a “best buy,” and any program costing less than US$ 36.9 million and US$ 94.5 million would
be “very cost effective” and “cost effective,” respectively. The analogous program cost thresh-
olds in the worst case scenario were US$ 341,500, US$ 19.5 million, and US$ 58.4 million over
10 years, respectively.
Discussion
We report the first economic evaluation of a comprehensive program to prevent and control
ARF/RHD in a developing country setting. We found that the program dominated a “do-noth-
ing” approach and was cost saving in the base case scenario. The program also remained cost-
effective in several scenario analyses, including a 20-fold increase in program costs. There are
three key findings of our analysis that are highly relevant beyond the Cuban population.
Firstly, our analysis suggests that previous cost-effectiveness studies of ARF/RHD control
[5, 9, 10] might have missed a crucial element: synergy between primary and secondary preven-
tion. In the Pinar del Rio program, the absolute risk reduction in new diagnoses of ARF (i.e., ef-
fect of primary prevention) was observed to be 83%, and the reduction in recurrent attacks of
ARF (i.e., effect of secondary prevention) 94%. The combination of interventions likely led to a
larger and more rapid reduction in the total burden of ARF and RHD in the population (and
Fig 2. Uncertainty and scenario analyses: variation in incremental cost-effectiveness ratio of the ARF/
RHD program compared to a “do-nothing” strategy. All costs are in 2010 US dollars.
doi:10.1371/journal.pone.0121363.g002
Cost-Effectiveness of a Rheumatic Heart Disease Program in Cuba
PLOSONE | DOI:10.1371/journal.pone.0121363 March 13, 2015 8 / 12
expenditures on these conditions) than would be observed with selective implementation of ei-
ther primary or secondary prevention in isolation. This combined approach makes sense from
an infectious disease dynamics standpoint, yet it has not been represented in studies that have
only considered the choice between primary and secondary prevention (and in some cases, car-
diac surgery).
Secondly, we demonstrated that the program’s cost (US$ 202,890) was modest in compari-
son to acceptable levels of expenditure using standard cost-effectiveness thresholds. Large sav-
ings in direct medical expenditures on advanced medical and surgical care were the drivers of
our high acceptability thresholds. Thus, while RHD is an uncommon disease (even in endemic
countries), it carries a high health and economic burden that is almost completely preventable
with existing technologies.
These program costs provide an important starting point for planning ARF/RHD control
programs in other settings. The cost of the intervention in Pinar del Rio was about US$ 0.07
per at-risk child per year, which is comparable to the cost of recommended interventions for
other neglected tropical diseases, e.g., mass drug administration for lymphatic filariasis [26].
Again, like mass drug administration for parasitic diseases, and in contrast to pharmacologic
treatment of many other chronic non-communicable diseases, this cost represents an up-front
investment that could lead to better control of the condition in the long run [12].
Thirdly, the findings of this study have immediate implications for policymaking in endem-
ic regions such as sub-Saharan Africa, South Asia, and the Asia Pacific region. In these settings,
scale-up of RHD programs is often hindered by lack of recognition of RHD as an important
public health problem, political barriers, and budgetary constraints. The results of our analysis
suggest that, even in low-resource settings, inaction on RHD is much more costly than action.
Furthermore, it is possible that investments in ARF/RHD control could have synergies with
other global and local initiatives to strengthen the delivery of primary care, particularly to
children [27].
The Cuban experience demonstrated that ARF/RHD control could be feasibly integrated
into existing public health services. In other settings, investments in ARF/RHD control, such as
(1) improvements in supply chains of penicillin, (2) health care provider training on manage-
ment of a common outpatient condition (pharyngitis), and (3) development of disease regis-
ters, could have a spillover effect and contribute more broadly to health system strengthening
in low-resource settings [28]. In this sense, low cost, highly effective ARF/RHD initiatives rep-
resent a “best buy” in global health and should be added to WHO’s list of highest-priority inter-
ventions for non-communicable diseases [23]. One example of such an initiative is the Stop
Rheumatic Heart Disease A.S.A.P. Programme that has been proposed by the Pan-African So-
ciety of Cardiology and supported by the World Heart Federation [27, 29].
Our study has some important limitations. First, we did not have access to individual-level
data over the study period and thus had to estimate transition probabilities from aggregate
data. Second, we did not have a true counterfactual comparator, but rather global and regional
trends. Third, the fact that the program occurred over 20 years ago in a centrally planned econ-
omy makes an accurate cost assessment challenging. Most relevant to developing countries in
the present day, the labor costs in Cuba were inexpensive during the study period (about $1
per hour on average), and thus the costs might not be generalizable to settings with higher
wages. On the other hand, conversion of Cuban Pesos to US dollars and use of medical costs
charged to foreigners may over-estimate the cost denominator. We did, attempt to address all
these limitations in the scenario analyses, and our findings were substantively similar across a
wide range of assumptions.
The results of this study should be interpreted with some caution. In addition to the caveats
above, we should note that there was full access to cardiac surgery in Cuba during the Pinar del
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Rio program; thus it is possible that the case for prevention in Cuba (especially as a cost-saving
measure) could be much stronger than, e.g., in a very resource-limited area without surgical ac-
cess. On the other hand, we were unable to capture the broader health system effects of the
Cuban program in our model. As discussed above, it is possible that such effects could make a
strong case for prevention, even without the additional savings in surgical expenditures.
Despite these limitations and caveats, our analysis suggests three important directions for
future research. Firstly, the results of this program, as well as similar programs in the Caribbean
[13, 30], have not been replicated since the late 1990s. Assessments of the effectiveness of ARF/
RHD programs currently underway [27] will provide more relevant inputs and assumptions
for future economic evaluations. Secondly, future cost-effectiveness studies of ARF/RHD pre-
vention should include scenarios where combined primary and secondary prevention are as-
sessed alongside isolated interventions. It is possible that short-term budgetary constraints in
very low-resource settings could make large-scale combined preventative or surgical interven-
tions difficult to implement, even if they are highly effective. Finally, it will be necessary to con-
duct operational/implementation science research on how to optimize delivery of ARF/RHD
interventions within the existing healthcare infrastructure. Such research will shed light on the
possibilities for health system strengthening through investment in ARF/RHD control.
Conclusions
We conclude that a 10-year program to control ARF and reduce the burden of RHD in Pinar
del Rio, Cuba was cost saving. The results of our analysis were robust to large increases in the
program’s cost and more conservative assumptions about the program’s net effects, and in fact,
even in the worst case scenario, there is an 88% chance that such a program is a “best buy” in
global health. It is likely that the effectiveness of the Cuban program arose from synergistic ef-
fects of primary and secondary prevention activities within the comprehensive framework. The
findings of this study have important implications for policymaking in other limited resource
regions, where similar programs could be undertaken to reduce the health and economic im-
pact of ARF/RHD.
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